Scott Rottinghaus - Enanta Pharmaceuticals VP Officer
| ENTA Stock | USD 6.20 0.11 1.74% |
Insider
Scott Rottinghaus is VP Officer of Enanta Pharmaceuticals
| Address | 4 Kingsbury Avenue, Watertown, MA, United States, 02472 |
| Phone | 617 607 0800 |
| Web | https://www.enanta.com |
Scott Rottinghaus Latest Insider Activity
Tracking and analyzing the buying and selling activities of Scott Rottinghaus against Enanta Pharmaceuticals stock is an integral part of due diligence when investing in Enanta Pharmaceuticals. Scott Rottinghaus insider activity provides valuable insight into whether Enanta Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Enanta Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Enanta Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Scott Rottinghaus over three months ago Disposition of 4299 shares by Scott Rottinghaus of Enanta Pharmaceuticals at 15.07 subject to Rule 16b-3 | ||
Scott Rottinghaus over six months ago Disposition of 2271 shares by Scott Rottinghaus of Enanta Pharmaceuticals at 15.04 subject to Rule 16b-3 | ||
Scott Rottinghaus over six months ago Disposition of 4299 shares by Scott Rottinghaus of Enanta Pharmaceuticals at 15.07 subject to Rule 16b-3 |
Enanta Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1775) % which means that it has lost $0.1775 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.691) %, meaning that it created substantial loss on money invested by shareholders. Enanta Pharmaceuticals' management efficiency ratios could be used to measure how well Enanta Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.34. The current year's Return On Capital Employed is expected to grow to -0.42. At present, Enanta Pharmaceuticals' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 5.6 M, whereas Total Assets are forecasted to decline to about 333.8 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jeffrey Ecsedy | Ikena Oncology | 55 | |
| Charles Newton | Lyell Immunopharma | 53 | |
| Owen Wallace | Monte Rosa Therapeutics | 55 | |
| Steve Andre | Cullinan Oncology LLC | N/A | |
| Kevin Capps | Crinetics Pharmaceuticals | N/A | |
| Stephanie Yao | Kronos Bio | N/A | |
| Cecilia Geuijen | Merus BV | N/A | |
| Hennie Hoogenboom | Merus BV | N/A | |
| Dawn Giangiulio | Design Therapeutics | N/A | |
| Julie CPA | Design Therapeutics | N/A | |
| Kevan Shokat | Revolution Medicines | N/A | |
| Jack Anders | Revolution Medicines | 49 | |
| Kristina Zambouras | C4 Therapeutics | N/A | |
| Ellen MBA | Werewolf Therapeutics | 48 | |
| Mark Wallet | Century Therapeutics | N/A | |
| Michael Fischbach | Revolution Medicines | 44 | |
| Gregory Russotti | Century Therapeutics | 58 | |
| Nellie Dillery | Lyell Immunopharma | N/A | |
| Elizabeth Homans | Lyell Immunopharma | 58 | |
| Behrad Derakhshan | Edgewise Therapeutics | 45 | |
| Aseem Ansari | Design Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.18 |
Enanta Pharmaceuticals Leadership Team
Elected by the shareholders, the Enanta Pharmaceuticals' board of directors comprises two types of representatives: Enanta Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enanta. The board's role is to monitor Enanta Pharmaceuticals' management team and ensure that shareholders' interests are well served. Enanta Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enanta Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jay Luly, CEO and President and Director | ||
| Scott MD, Senior Officer | ||
| Nathalie MD, Consultant | ||
| Jennifer Viera, Executive Communications | ||
| Nathaniel JD, General VP | ||
| Tara Kieffer, Senior Development | ||
| Brendan Luu, Senior Development | ||
| Matthew JD, Chief Secretary | ||
| Paul Mellett, CFO and Sr. VP of Fin. and Admin. | ||
| Yat Or, Chief Scientific Officer and Sr. VP of RandD | ||
| Scott Rottinghaus, VP Officer |
Enanta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Enanta Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (1.58) % | ||||
| Operating Margin | (1.39) % | ||||
| Current Valuation | (26.97 M) | ||||
| Shares Outstanding | 21.33 M | ||||
| Shares Owned By Insiders | 6.57 % | ||||
| Shares Owned By Institutions | 96.10 % | ||||
| Number Of Shares Shorted | 3.57 M | ||||
| Price To Earning | 366.13 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enanta Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Enanta Stock refer to our How to Trade Enanta Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enanta Pharmaceuticals. If investors know Enanta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enanta Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.66) | Earnings Share (4.95) | Revenue Per Share | Quarterly Revenue Growth (0.06) | Return On Assets |
The market value of Enanta Pharmaceuticals is measured differently than its book value, which is the value of Enanta that is recorded on the company's balance sheet. Investors also form their own opinion of Enanta Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Enanta Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enanta Pharmaceuticals' market value can be influenced by many factors that don't directly affect Enanta Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enanta Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enanta Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enanta Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.